Mechanisms contributing to co-morbid psychosis in Alzheimer's disease
Mechanisms contributing to co-morbid psychosis in Alzheimer's disease
批准号:
10514575
负责人:
Daniel Lodge
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-10-01 至 2024-09-30
关键词:
AffectAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAmericanAntipsychotic AgentsAutopsyBehaviorBehavioralBeliefCell TransplantationDelusionsDementiaDevelopmentDiseaseDopamineElderlyElectrophysiology (science)ExonsFunctional disorderGenerationsGlutamatesHallucinationsHippocampusHumanInjuryInterneuron functionInterneuronsKnock-inLocomotionMemoryMidbrain structureMilitary PersonnelModelingMutationNeuronsParvalbuminsPathologicPathologyPatientsPharmaceutical PreparationsPlayPopulationPost-Traumatic Stress DisordersPrevalencePsychosesRattusRegulationReportingRodent ModelRoleSchizophreniaServicesSignal TransductionSiteSomatostatinStem cell transplantStimulantStructureSwedish mutationSymptomsTherapeuticToxic effectTransplantationTraumatic Brain InjuryUnited States Food and Drug AdministrationVentral Tegmental AreaVeteransassociated symptomcare costscholinergiccomorbiditydisorder riskdopamine systemdopaminergic neuroneffective therapyextracellularin vivomilitary veteranmortality riskneurotransmissionnew therapeutic targetnovelnovel therapeutic interventionpharmacologicpositive allosteric modulatorprepulse inhibitionpresenilin-1preservationpsychotic symptomsreceptorresponsespatial memory
中文摘要
项目摘要/摘要:
精神病症状(幻觉和妄想)是阿尔茨海默病中非常普遍的疾病。不幸的是,
用于治疗精神病的抗精神病药物在老年人中是禁忌的,因为食品和药物
美国食品和药物管理局 (FDA) 对所有第一代和第二代抗精神病药物发出黑框警告
表明这些药物会增加老年痴呆症患者的死亡风险。我们已经证明了
海马体在多巴胺系统功能的调节中起着核心作用,并且异常
海马对多巴胺神经元活动的调节可能导致精神分裂症的精神病。鉴于此
海马体是 AD 病理的关键部位,我们推测海马体可能是汇聚部位
导致 AD 中的共病精神病,我们将使用啮齿动物模型来研究这一假设。具体来说,
我们将检查多巴胺神经元活动的基础活动和传入调节以及行为相关性
两种不同 AD 啮齿动物模型中精神病的研究(目标 1)。然后我们将检查 AD 病理学的后果
vHipp 中间神经元功能以及是否移植干细胞衍生的中间神经元(目标 2)或
海马功能的药理学调节(目标 3)可以逆转异常的神经元活动
AD 模型中的行为。因此,该提案确定了一个潜在的新治疗靶点,并告知
开发针对 AD 和共病精神病的更有效的治疗方法。
英文摘要
Project Summary/Abstract:
Psychotic symptoms (hallucinations and delusions) are highly prevalent Alzheimer's disease. Unfortunately, the
antipsychotic medications used to treat psychosis are contraindicated in the elderly where the Food and Drug
Administration (FDA) issued a black-box warning for all first- and second-generation antipsychotic medications
indicating that these drugs increase the risk of death in elderly dementia patients. We have demonstrated that
the hippocampus plays a central role in the regulation of dopamine system function and that aberrant
hippocampal regulation of dopamine neuron activity likely contributes to psychosis in schizophrenia. Given that
the hippocampus is a key site of pathology in AD, we posit that the hippocampus may be a site of convergence
contributing to comorbid psychosis in AD, and we will use rodent models to study this hypothesis. Specifically,
we will examine basal activity and afferent regulation of dopamine neuron activity as well as behavioral correlates
of psychosis in two distinct rodent models of AD (Aim 1). We will then examine the consequence of AD pathology
on vHipp interneuron function and whether transplantation of stem cell derived interneurons (Aim 2) or
pharmacological modulation of hippocampal function (Aim 3) can reverse aberrant neuronal activity and
behavior in AD models. This proposal with therefore identify a potential novel therapeutic target and inform the
development of more effective treatment approaches for AD and comorbid psychosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aberrant dopamine system function in a rodent model of perimenopause: relevance to psychosis
-
批准号:10585490
-
项目类别:
-
资助金额:$31.72万
-
财政年份:2023
-
负责人:Daniel Lodge
-
依托单位:
The Orexin System as a Target for PTSD and Comorbid Psychosis
-
批准号:10618914
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Daniel Lodge
-
依托单位:
Mechanisms contributing to co-morbid psychosis in Alzheimer's disease
-
批准号:10012453
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Daniel Lodge
-
依托单位:
The Orexin System as a Target for PTSD and Comorbid Psychosis
-
批准号:10454782
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Daniel Lodge
-
依托单位:
Mechanisms contributing to co-morbid psychosis in Alzheimer's disease
-
批准号:10293545
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Daniel Lodge
-
依托单位:
The Orexin System as a Target for PTSD and Comorbid Psychosis
-
批准号:9891460
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Daniel Lodge
-
依托单位:
Adiponectin regulation of the mesolimbic dopamine system
-
批准号:8228413
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2012
-
负责人:Daniel Lodge
-
依托单位:
Adiponectin regulation of the mesolimbic dopamine system
-
批准号:8432434
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2012
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:9304377
-
项目类别:
-
资助金额:$35.75万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:8073091
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:8287656
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:8488474
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:9024375
-
项目类别:
-
资助金额:$48.81万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:7992580
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
Regulation of ventral hippocampal system function
-
批准号:8685327
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2010
-
负责人:Daniel Lodge
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: